1
Country: USA | Funding: $1.2B
Vir Biotechnology develops immunotherapeutics for the treatment and prevention of infectious diseases, including Flu and Covid19. Its next-generation antibody platform and PRO-XTEN protease-release masking technology are designed to treat infectious diseases and cancer, respectively. The company uses the dAIsY (Data Structure and Antibody AI) platform to design and optimize drug candidates, modulating interactions with the immune system and improving key characteristics that help us create more effective drugs faster. Vir is advancing several candidates for the treatment of hepatitis delta, solid tumors and HIV.
Vir Biotechnology develops immunotherapeutics for the treatment and prevention of infectious diseases, including Flu and Covid19. Its next-generation antibody platform and PRO-XTEN protease-release masking technology are designed to treat infectious diseases and cancer, respectively. The company uses the dAIsY (Data Structure and Antibody AI) platform to design and optimize drug candidates, modulating interactions with the immune system and improving key characteristics that help us create more effective drugs faster. Vir is advancing several candidates for the treatment of hepatitis delta, solid tumors and HIV.
2
Country: USA | Funding: $213.1M
Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral
Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral
3
Country: USA | Funding: $125.4M
Visterra is a clinical-stage biopharmaceutical company focused on applying its novel Hierotope platform to identify unique disease targets and to design and engineer precision antibody-based biological medicines for infectious and non-infectious diseases.
Visterra is a clinical-stage biopharmaceutical company focused on applying its novel Hierotope platform to identify unique disease targets and to design and engineer precision antibody-based biological medicines for infectious and non-infectious diseases.
4
Country: China | Funding: $96.3M
Sinovac Biotech is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu) ...
Sinovac Biotech is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu) ...
5
Country: USA | Funding: $65.6M
Codagenix employs a proprietary technology platform for the construction of live attenuated viral vaccines for flu and other targets.
Codagenix employs a proprietary technology platform for the construction of live attenuated viral vaccines for flu and other targets.
6
Country: Australia
Vaxine is focused on development of innovative vaccine technologies. Vaxine’s human candidates include vaccines against seasonal and pandemic influenza, hepatitis B, Japanese encephalitis, West Nile Virus, malaria, rabies, and allergy.
Vaxine is focused on development of innovative vaccine technologies. Vaxine’s human candidates include vaccines against seasonal and pandemic influenza, hepatitis B, Japanese encephalitis, West Nile Virus, malaria, rabies, and allergy.
